Cancer Immunotherapy Peptides

Peptide PD-1/PD-L1 Inhibitors vs Antibodies

Peptide PD-1/PD-L1 inhibitors offer better tumor penetration, lower cost, and tunable half-life compared to antibodies. Here is where the research stands.